Last reviewed · How we verify
Standard bupivicaine
Standard bupivicaine, developed by Emory University, is a marketed anesthetic with a well-established presence in the healthcare sector. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market stability. The primary risk lies in potential generic competition following the patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Standard bupivicaine |
|---|---|
| Also known as | bupivicaine, Marcaine |
| Sponsor | Emory University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Regional Nerve Blocks to Improve Analgesia and Recovery in Older Adults Undergoing Spinal Fusion (EARLY_PHASE1)
- Exparel Versus Bupivacaine in Post-operative Pain Control (PHASE4)
- Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder (PHASE3)
- 0.5% Bupivacaine Lower Cervical Intramuscular Injection vs IV Medications for Headache Treatment (PHASE3)
- Analgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion (PHASE2, PHASE3)
- RCT Comparing ESPB Solutions in Breast Surgery (PHASE2)
- Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine (PHASE2)
- Laparoscopically Guided Rectus Sheath Block in Pediatric Appendicitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard bupivicaine CI brief — competitive landscape report
- Standard bupivicaine updates RSS · CI watch RSS
- Emory University portfolio CI